The estimated Net Worth of Stacy J. Kanter is at least $492 Tisíc dollars as of 1 December 2023. Ms. Kanter owns over 30,000 units of Applied Therapeutics stock worth over $328,230 and over the last 6 years she sold APLT stock worth over $0. In addition, she makes $164,269 as Independent Director at Applied Therapeutics.
Sign up
Ms. Kanter APLT stock SEC Form 4 insiders trading
Stacy has made over 3 trades of the Applied Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 30,000 units of APLT stock worth $65,400 on 1 December 2023.
The largest trade she's ever made was buying 30,000 units of Applied Therapeutics stock on 1 December 2023 worth over $65,400. On average, Stacy trades about 3,909 units every 128 days since 2019. As of 1 December 2023 she still owns at least 63,000 units of Applied Therapeutics stock.
You can see the complete history of Ms. Kanter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stacy Kanter biography
Stacy J. Kanter J.D. serves as Independent Director of the Company. Ms. Kanter practiced law for more than 30 years with Skadden, Arps, Slate, Meagher & Flom LLP, where she was a partner from 1993 until December 2018 and Head of the Global Capital Markets practice from 2009 until December 2018 and was Of Counsel from January 2019 until joining our board of directors. Ms. Kanter also chaired Skadden’s Global Diversity and Inclusion Committee. Ms. Kanter was an associate at Skadden from 1984 to 1986 and from 1988 to 1993. Ms. Kanter served as a law clerk to the Honorable Raymond J. Dearie, United States District Court Judge for the Eastern District of New York from 1986 to 1987. Ms. Kanter received her B.S. in Business Administration and Management from the University at Albany School of Business and her J.D. from Brooklyn Law School. Ms. Kanter was identified as a potential candidate by our Chief Executive Officer, and following an independent third party review process, recommended to the nominating and corporate governance committee and later approved by the board.
What is the salary of Stacy Kanter?
As the Independent Director of Applied Therapeutics, the total compensation of Stacy Kanter at Applied Therapeutics is $164,269. There are 9 executives at Applied Therapeutics getting paid more, with shoshana Shendelman having the highest compensation of $11,590,000.
How old is Stacy Kanter?
Stacy Kanter is 61, she's been the Independent Director of Applied Therapeutics since 2019. There are 4 older and 7 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
What's Stacy Kanter's mailing address?
Stacy's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Insiders trading at Applied Therapeutics
Over the last 6 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus a Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
What does Applied Therapeutics do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
What does Applied Therapeutics's logo look like?
Complete history of Ms. Kanter stock trades at Oppenheimer Inc a Applied Therapeutics
Applied Therapeutics executives and stock owners
Applied Therapeutics executives and other stock owners filed with the SEC include:
-
shoshana Shendelman,
Chairman of the Board, President, Chief Executive Officer, Founder -
Riccardo Perfetti,
Chief Medical Officer -
Mark Vignola,
Chief Financial Officer -
Dr. Shoshana Shendelman Ph.D.,
Chair of the Board of Directors, Founder, Pres, CEO & Sec. -
Dr. Riccardo Perfetti,
Chief Medical Officer -
Leslie Funtleyder,
Independent Director -
Dr. Charles Silberstein M.D., CFA,
CFO & Head of Bus. Devel. -
Teena Lerner,
Lead Independent Director -
Joel Marcus,
Independent Director -
Stacy Kanter,
Independent Director -
Jay Skyler,
Independent Director -
Maeve Conneighton,
IR Contact Officer -
Adam Hansard,
Chief Commercial Officer -
Chids Mahadevan,
VP of Fin. & Chief Accounting Officer -
Real Estate Equities, Inc.A...,
-
Constantine Chinoporos,
See Remarks -
Charles Silberstein,
Chief Financial Officer -
Adam Hansard,
Chief Commercial Officer -
Corwin Dale Hooks,
Chief Commercial Officer -
Steven A. Ortega,
Principal Accounting Officer -
Chids Mahadevan,
See Remarks